About Affinium Pharmaceuticals
Affinium Pharmaceuticals is a company based in Toronto (Canada) founded in 2000 was acquired by Debiopharm in February 2014.. Affinium Pharmaceuticals has raised $33 million across 3 funding rounds from investors including Debiopharm, Forward Ventures and Venture Ontario. Affinium Pharmaceuticals operates in a competitive market with competitors including Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others.
- Headquarter Toronto, Canada
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$33 M (USD)
in 3 rounds
-
Latest Funding Round
$18.9 M (USD), Debt – Conventional
Sep 09, 2013
-
Investors
Debiopharm
& 5 more
-
Employee Count
Employee Count
-
Acquired by
Debiopharm
(Feb 11, 2014)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Affinium Pharmaceuticals
Affinium Pharmaceuticals has successfully raised a total of $33M across 3 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $18.9 million completed in September 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Debt – Conventional — $18.9M
-
First Round
First Round
(26 Mar 2007)
- Investors Count 5
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep, 2013 | Amount | Debt – Conventional - Affinium Pharmaceuticals | Valuation |
investors |
|
| Aug, 2011 | Amount | Series B - Affinium Pharmaceuticals | Valuation | Ontario Capital Growth Corporation | |
| Mar, 2007 | Amount | Series A - Affinium Pharmaceuticals | Valuation | Forward Ventures |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Affinium Pharmaceuticals
Affinium Pharmaceuticals has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Debiopharm, Forward Ventures and Venture Ontario. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Sciences focused VC firm that does early stage investments in the US
|
Founded Year | Domain | Location | |
|
Venture capital investments are managed for Ontario's technology sector.
|
Founded Year | Domain | Location | |
|
Early-stage life sciences companies are supported through venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Affinium Pharmaceuticals
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Affinium Pharmaceuticals
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Affinium Pharmaceuticals Comparisons
Competitors of Affinium Pharmaceuticals
Affinium Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Paratek Pharma, Spero Therapeutics, Cempra, Bugworks Research and Locus Biosciences, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for antimicrobial resistant infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for drug-resistant bacterial infections are developed.
|
|
| domain | founded_year | HQ Location |
Clinical-stage pharmaceutical company focused on developing antibacterials
|
|
| domain | founded_year | HQ Location |
Drugs for antibiotic-resistant infections and cancer are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutics for infectious disease and inflammatory indications
|
|
| domain | founded_year | HQ Location |
Therapies for multi-drug resistant infections are developed using bacteriophages.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Affinium Pharmaceuticals
Frequently Asked Questions about Affinium Pharmaceuticals
When was Affinium Pharmaceuticals founded?
Affinium Pharmaceuticals was founded in 2000 and raised its 1st funding round 7 years after it was founded.
Where is Affinium Pharmaceuticals located?
Affinium Pharmaceuticals is headquartered in Toronto, Canada. It is registered at Toronto, Ontario, Canada.
Is Affinium Pharmaceuticals a funded company?
Affinium Pharmaceuticals is a funded company, having raised a total of $33M across 3 funding rounds to date. The company's 1st funding round was a Series A of $18M, raised on Mar 26, 2007.
What does Affinium Pharmaceuticals do?
Affinium Pharmaceuticals was a Canadian, clinical stage biopharma developing bacterial FAS II-inhibitors, highly specific to Staphylococcus sp. As of February 11, 2014, Affinium Pharmaceuticals was acquired by Debiopharm Group. The company has a proprietary antibacterial platform that targets bacterial fatty acid synthesis. The company was developing AFN-1252, and its pro-drug, AFN-1720 for the oral and IV treatment of staphylococcal infections (tested on 5400 strains), including methicillin-resistant S. aureus (MRSA), and vancomycin-intermediate S. aureus (VISA). At the time of acquisition, AFN-1252 had completed a Phase 2a study for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and AFN-1720 was in Phase 1 clinical development. Affinium was previously called Integrative Proteomics, Inc.
Who are the top competitors of Affinium Pharmaceuticals?
Affinium Pharmaceuticals's top competitors include Spero Therapeutics, Melinta Therapeutics and Vedanta Biosciences.
Who are Affinium Pharmaceuticals's investors?
Affinium Pharmaceuticals has 6 investors. Key investors include Debiopharm, Forward Ventures, Venture Ontario, Genesys Capital, and SV Health Investors.